Is the price fair?
What HUM's price assumes
Humana trades at 43.0× earnings against 25.6× for the median Healthcare Plans name, more expensive than its own group.
43.0
Trailing P/E · Healthcare Plans median 25.6 · 1.68× the median: the market pays up for this one
- Price / sales
- 0.15
Price / sales · as of 2026-Q1
- Free cash flow yield
- 2.9%
Free cash flow yield · Healthcare Plans median 6.5%
- Growth the price implies
- +13%
Growth the price implies · The price pays for +13% free cash flow growth a year for a decade; the business has delivered −50% a year over the last three.
Details›
- Price / book2026-Q1
- 1.13
- EV / EBIToperating margin 1.8%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 0.21
- Healthcare median P/E362 names
- 29.9
- Healthcare Plans median P/E11 names
- 25.6
- Free cash flow, trailing twelve months
- $1.27B
- Market capitalisation
- $43.3B
- 3-year revenue growth
- +13%
- 3-year free cash flow growth
- −50%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $162.91 |
| Its own P/E history, median | $184.19 |
| Its own P/E history, upper quartile | $208.31 |
| 52-week range | $162.84 – $407.89 |
| Today | $403.02 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.